Investor Overview

Investors

Additional Resources

Shareholder Tools

Print Page
Email Page
Email Alerts
RSS Feeds
Financial Tear Sheet

NASDAQ: XBIT0.5310.41Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News

Date	Title
03/05/19	Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics
03/01/19	Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting
01/29/19	Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting

Upcoming Events

There are currently no events scheduled.